SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...
In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
The proposed Medicare coverage change could help Edwards Lifesciences gain market share from Medtronic and Boston Scientific, an analyst said.
Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...
Transcatheter aortic valve replacement (TAVR) devices continue to make a splash in the world of medical technology, with the Sapien 3 by Edwards Lifesciences Corp. leading the way. Results of the ...
Edwards Lifesciences Corp. EW is scheduled to report third-quarter 2025 results on Oct. 30, after market close. In the last reported quarter, the company’s adjusted earnings per share of 67 cents beat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results